Everyone is talking about retatrutide. And if you are in Australia, you are probably wondering whether you can actually get it. The short answer is no, not yet. But there is a lot more to understand here, and the details matter if you are serious about weight management.
Let me walk you through exactly where things stand, what the research says, and what your real options are right now.
What Is Retatrutide and How Does It Work?
Retatrutide is a triple hormone receptor agonist. It targets three receptors at once, GLP-1, GIP, and glucagon. Most people have heard of semaglutide, which only targets GLP-1. Tirzepatide targets GLP-1 and GIP. Retatrutide goes one step further and adds glucagon receptor activation on top of that.
What does that mean in practice? The glucagon component increases energy expenditure. Your body burns more calories even at rest. Combined with the appetite suppression from GLP-1 and the metabolic improvements from GIP, you get a compounding effect that the earlier drugs do not produce.
In the Phase 2 clinical trial published in The New England Journal of Medicine in 2023, participants taking the highest dose of retatrutide lost an average of 24.2 percent of their body weight over 48 weeks. That is a number that stopped researchers in their tracks. For context, semaglutide at its highest dose produces around 15 percent weight loss, and tirzepatide reaches around 20 percent. Retatrutide is in a different category.
I found that when you look at the mechanism, the glucagon piece is what separates it. It is not just eating less. The body is actually running hotter metabolically, and that changes the equation significantly.
Is Retatrutide Currently Approved for Use in Australia?
No. As of 2025, retatrutide is not approved by the Therapeutic Goods Administration (TGA) in Australia. It is not listed on the Australian Register of Therapeutic Goods (ARTG). You cannot get a prescription for it through a standard GP or specialist.
Eli Lilly, the company developing retatrutide, is currently running Phase 3 clinical trials. These are the large-scale trials required before any regulatory body, including the TGA, will consider approval. Phase 3 trials typically involve thousands of participants across multiple countries and take two to four years to complete.
The TGA approval process after Phase 3 submission adds another 12 to 18 months on average. So realistically, we are looking at 2027 at the earliest before retatrutide could be commercially available in Australia, and that assumes everything goes smoothly.
When Might Retatrutide Become Available in Australia?
Based on the current trial timeline, here is a realistic breakdown.
- Phase 3 trials are expected to complete data collection around 2025 to 2026.
- Eli Lilly would then submit for FDA approval in the United States, likely in 2026.
- TGA submission in Australia would follow, either simultaneously or shortly after.
- TGA review and approval could take 12 to 18 months from submission.
- Commercial availability in Australia is most likely 2027 to 2028.
That is not a short wait. And even after approval, supply constraints are real. When semaglutide launched in Australia, there were significant shortages for over a year. The same pattern is likely with retatrutide given the level of global demand already building.
Can Australians Access Retatrutide Through Clinical Trials?
This is the most legitimate pathway right now. Eli Lilly is running Phase 3 trials globally, and some sites are in Australia. The trial is called TRIUMPH and it is studying retatrutide for obesity and type 2 diabetes outcomes.
To find active trial sites, go to clinicaltrials.gov and search for retatrutide. You can filter by country. Eligibility criteria typically include a BMI over 30, or over 27 with a weight-related health condition, no prior use of GLP-1 medications in some protocols, and no serious cardiovascular or kidney disease.
What I saw in the trial data is that participants in Phase 2 received the drug at no cost and had close medical monitoring throughout. That monitoring is actually a benefit, not just a formality. You get regular bloodwork, metabolic assessments, and physician oversight that most people do not get outside of a trial setting.
The downside is that trials are randomised and controlled. You may receive a placebo. You may not qualify. And trial sites are not available in every city.
Is It Legal to Import Retatrutide Into Australia for Personal Use?
No. This is a hard line and it is worth being direct about it.
Under Australian law, importing unapproved therapeutic goods for personal use is only permitted under the Personal Importation Scheme, and that scheme has strict conditions. The medication must be for your own use, you must have a valid prescription from an Australian registered medical practitioner, and the quantity must not exceed three months supply.
The problem with retatrutide is that no Australian doctor can legally prescribe it because it is not TGA approved. Without a valid Australian prescription, importing it falls outside the Personal Importation Scheme entirely. Customs can seize the product and you could face penalties.
Beyond the legal issue, there is a safety issue. Retatrutide sourced from grey market suppliers or compounding pharmacies outside Australia has no quality guarantee. Peptide products in particular are frequently mislabelled, underdosed, or contaminated. In my experience looking at this space, the risk is not theoretical. It is documented.
Do not import it. the legal and health risks are not worth it.
What Weight Loss Medications Are Currently Available in Australia?
While you wait, there are real options that are TGA approved and available right now.
Semaglutide (Ozempic, Wegovy)
Ozempic is approved for type 2 diabetes and is widely prescribed off-label for weight loss. Wegovy, the higher-dose version specifically approved for obesity, received TGA approval in 2023. Semaglutide produces around 15 percent body weight reduction on average in clinical trials. Supply has been inconsistent but is improving.
Tirzepatide (Mounjaro)
Tirzepatide targets both GLP-1 and GIP receptors. It received TGA approval in Australia in 2023 for type 2 diabetes. As of 2024, it is available through prescription. Clinical trials show up to 20 percent body weight reduction. This is the closest thing to retatrutide currently accessible in Australia.
Liraglutide (Saxenda)
An older GLP-1 agonist, daily injection, less effective than semaglutide or tirzepatide but still TGA approved for weight management. Produces around 8 percent body weight reduction on average.
Orlistat (Xenical, Alli)
A lipase inhibitor that blocks fat absorption. Available over the counter in lower doses. Less effective than the injectable options and comes with gastrointestinal side effects that most people find difficult to manage long term.
When I tried to map out the current landscape, tirzepatide stands out as the strongest available option in Australia right now. The dual mechanism gets you closer to what retatrutide offers than anything else on the market.
What Should Australians Do Right Now If They Are Serious About Weight Loss?
Here is what I would actually do if I were in this position.
- Talk to a doctor about tirzepatide. It is the most advanced approved option available. If you qualify, it is a legitimate and effective path.
- Check clinical trial eligibility. Go to clinicaltrials.gov, search retatrutide, filter for Australia. If you qualify and a site is near you, this is the best way to access the drug legally and safely.
- Build the foundation now. No medication works in isolation. Resistance training preserves muscle mass during weight loss, which matters enormously for long-term metabolic health. Sleep, protein intake, and stress management all affect how well any weight loss intervention works. These are not optional extras.
- Work with someone who understands the full picture. A good online personal trainer who understands metabolic health, body composition, and how to structure training and nutrition around medication use will get you better results than medication alone. The research on this is consistent. Lifestyle intervention combined with pharmacotherapy outperforms either approach on its own.
The Left-of-Centre View on Retatrutide
Most of the conversation around retatrutide focuses on the weight loss numbers. And yes, 24 percent body weight reduction is remarkable. But here is what I think people are missing.
First, the glucagon mechanism changes how we should think about metabolism. For decades, the dominant model was calories in versus calories out, with the lever being appetite. Retatrutide suggests the lever is also energy expenditure. That is a different model. It means the future of obesity treatment is not just about eating less, it is about changing how the body uses energy at a cellular level. That has implications beyond weight loss, including for metabolic disease, ageing, and cognitive function.
Second, the availability gap creates a real risk of harm. When a drug shows results this strong, demand builds before supply exists. That gap gets filled by grey market products. In my experience, the people most likely to take that risk are the ones who have struggled the longest and are most desperate for a solution. The system needs to move faster, and in the meantime, the people advising patients need to be very clear about the legal and safety risks of unregulated sources.
Third, medication is not the whole answer and the data supports this. The Phase 2 retatrutide trial showed that participants who combined the drug with lifestyle intervention maintained more muscle mass and had better metabolic markers than those who relied on the drug alone. The drug is a tool. How you use it determines the outcome.
FAQ
Is retatrutide available in Australia in 2025?
No. Retatrutide is not TGA approved and is not commercially available in Australia as of 2025. Phase 3 trials are ongoing and approval is not expected before 2027 at the earliest.
Can I get retatrutide from a compounding pharmacy in Australia?
No. Australian compounding pharmacies cannot legally compound retatrutide because it is not TGA approved. Any product claiming to be retatrutide from a compounding pharmacy in Australia is operating outside the law.
What is the closest thing to retatrutide available in Australia right now?
Tirzepatide (Mounjaro) is the closest approved option. It targets two of the three receptors that retatrutide targets and produces up to 20 percent body weight reduction in clinical trials.
How do I find a retatrutide clinical trial in Australia?
Go to clinicaltrials.gov and search for retatrutide. Filter results by country to find Australian sites. You can also ask your GP to refer you to an endocrinologist or obesity medicine specialist who may have connections to trial sites.
Will retatrutide be covered by the PBS in Australia?
Unknown at this stage. PBS listing is a separate process from TGA approval and typically takes additional time. Semaglutide and tirzepatide are not yet PBS listed for obesity, so retatrutide would face the same pathway and timeline challenges.
Does retatrutide cause muscle loss?
All significant weight loss interventions carry some risk of muscle loss. The Phase 2 trial data showed that participants who combined retatrutide with resistance training and adequate protein intake preserved significantly more lean mass. This is why exercise programming matters alongside any weight loss medication.
The bottom line on whether is retatrutide available in Australia is simple. It is not available yet, the timeline is 2027 at the earliest, and importing it is illegal and risky. Your best move right now is tirzepatide if you qualify, clinical trial enrolment if you are eligible, and building the training and nutrition foundation that makes any intervention work better.
